Loading clinical trials...
Loading clinical trials...
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
Conditions
Interventions
DD01
Placebo
Locations
4
United States
Prosciento
Chula Vista, California, United States
Southwest General Healthcare Center
Fort Myers, Florida, United States
Combined Research Orlando
Orlando, Florida, United States
FDI Clinical Research
San Juan, Puerto Rico
Start Date
February 24, 2021
Primary Completion Date
December 20, 2022
Completion Date
February 14, 2023
Last Updated
April 29, 2024
NCT07265544
NCT06277232
NCT07395973
NCT05277558
NCT06599918
NCT04681573
Lead Sponsor
Neuraly, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions